Unknown

Dataset Information

0

GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells in vitro.


ABSTRACT: Immune evasion is a recently defined hallmark of cancer, and immunotherapeutic approaches that stimulate an immune response to tumours are gaining recognition. However tumours may evade the immune response and resist immune-targeted treatment by promoting an immune-suppressive environment and stimulating the differentiation or recruitment of immunosuppressive cells. Myeloid-derived suppressor cells (MDSC) have been identified in a range of cancers and are often associated with tumour progression and poor patient outcomes. Pancreatic cancer in particular supports MDSC differentiation via the secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF), and MDSC are believed to contribute to the profoundly immune-suppressive microenvironment present in pancreatic tumours. MDSC-targeted therapies that deplete or inhibit this cell population have been proposed as a way to shift the balance in favour of a tumour-clearing immune response. In this study, we have modelled MDSC differentiation and function in vitro and this has provided us with the opportunity to test a range of potential MDSC-targeted therapies to identify candidates for further investigation. Using in vitro modelling we show here that the combination of GM-CSF-signalling blockade and gemcitabine suppresses both the MDSC phenotype and the inhibition of T-cell function by MDSC.

SUBMITTER: Gargett T 

PROVIDER: S-EPMC5192067 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells <i>in vitro</i>.

Gargett Tessa T   Christo Susan N SN   Hercus Timothy R TR   Abbas Nazim N   Singhal Nimit N   Lopez Angel F AF   Brown Michael P MP  

Clinical & translational immunology 20161223 12


Immune evasion is a recently defined hallmark of cancer, and immunotherapeutic approaches that stimulate an immune response to tumours are gaining recognition. However tumours may evade the immune response and resist immune-targeted treatment by promoting an immune-suppressive environment and stimulating the differentiation or recruitment of immunosuppressive cells. Myeloid-derived suppressor cells (MDSC) have been identified in a range of cancers and are often associated with tumour progression  ...[more]

Similar Datasets

| S-EPMC3145786 | biostudies-literature
| S-EPMC4296557 | biostudies-literature
| S-EPMC8699038 | biostudies-literature
| S-EPMC7037240 | biostudies-literature
| S-EPMC6737278 | biostudies-literature
| S-EPMC6204844 | biostudies-literature
| S-EPMC1479425 | biostudies-literature
| S-EPMC5737598 | biostudies-literature
| S-EPMC5215529 | biostudies-other
| S-EPMC4046249 | biostudies-literature